Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ. Daemen A, et al. Among authors: frankum jr. Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9. Breast Cancer Res Treat. 2012. PMID: 22875744 Free PMC article.
Searching for synthetic lethality in cancer.
Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Brough R, et al. Among authors: frankum jr. Curr Opin Genet Dev. 2011 Feb;21(1):34-41. doi: 10.1016/j.gde.2010.10.009. Epub 2011 Jan 20. Curr Opin Genet Dev. 2011. PMID: 21255997 Review.
Functional characterization of EMSY gene amplification in human cancers.
Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS. Wilkerson PM, et al. J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7. J Pathol. 2011. PMID: 21735447
Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L; Breast Cancer Susceptibility Collaboration (UK); Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N. Loveday C, et al. Among authors: frankum jr. Nat Genet. 2011 Aug 7;43(9):879-882. doi: 10.1038/ng.893. Nat Genet. 2011. PMID: 21822267 Free PMC article.
Functional viability profiles of breast cancer.
Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A. Brough R, et al. Among authors: frankum jr. Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2. Cancer Discov. 2011. PMID: 21984977 Free PMC article.
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.
Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, Bajrami I, Brough R, Frankum J, Sharpe R, Marchio C, Horlings H, Reyal F, van der Vijver M, Turner N, Reis-Filho JS, Lord CJ, Ashworth A. Shiu KK, et al. Oncogene. 2014 Jan 30;33(5):619-31. doi: 10.1038/onc.2012.625. Epub 2013 Jan 21. Oncogene. 2014. PMID: 23334330 Free article.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: frankum jr. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
30 results